- Alternative Therapies
- Blood, Heart and Circulation
- Bones and Muscles
- Brain and Nerves
- Child health
- Cosmetic Surgery
- Digestive System
- Disorders and Conditions
- Drugs Approvals and Trials
- Environmental Health
- Ear, Nose and Throat
- Eyes and Vision
- Female Reproductive
- Genetics and Birth Defects
- Geriatrics and Aging
- Health Informatics
- Immune System
- Kidneys and Urinary System
- Legal and Regulatory
- Life style and Fitness
- Lungs and Breathing
- Male Reproductive
- Medical Breakthroughs
- Mental Health and Behavior
- Metabolic Problems
- Oral and Dental Health
- Palliative Care
- Pregnancy and Childbirth
- Public Health and Safety
- Sexual Health
- Skin, Hair and Nails
- Sports Medicine
- Substance Abuse
- Surgery and Rehabilitation
Researchers uncover new operations of cancer suppressor
Scientists at the University of Dundee studying an important tumour suppressor, which is involved in at least a quarter of all cancers, have uncovered new ways in which it works.
The research team at the College of Life Sciences at Dundee have been studying the tumour suppressor protein PTEN, which when 'turned off' or damaged drives the development of many cancers.
By studying brain tumour cells, the Dundee team led by Dr Nick Leslie found that some damaged PTEN proteins can still operate in many of their normal ways but importantly lose the ability to stop cancer cells invading the brain.
Brain tumours are particularly deadly, having a very poor prognosis, because although they rarely spread outside the brain, by the time they are diagnosed, some cancer cells have usually moved away from the original tumour and infiltrated the surrounding brain tissue. Therefore, when a surgeon removes the initial tumour, it is often not long before a second tumour grows from the few cancer cells in the surrounding brain tissue.
Dr Leslie's team set up experiments, using a 3D matrix similar to that found between cells in the brain, to investigate this process of how cancer cells invade from a tumour mass into healthy tissue. Their work, published in the journal Science Signalling, describes how PTEN controls the way these brain tumour cells grow, change their shape, switch particular genes on and off and importantly how PTEN normally stops this invasion process.
"We know that PTEN has lots of effects on what cells do, but it has proved harder to be certain which of these effects are important in stopping cancer and therefore which ones we should develop drugs to target," said Dr Leslie.
"It is really important we understand the factors driving these cancers, which affect thousands of people every year in the UK."
Dr Leslie said a lot was already known about one way in which PTEN can stop cells growing and dividing, but there have been several hints in the past that there are other undiscovered ways in which PTEN may stop cancers developing.
"In our new work, we've used two similarly damaged versions of PTEN, one of which was found in a tumour, that we show can still do the best recognised things that PTEN does, just as well as normal PTEN protein. However, these damaged proteins have completely lost the ability to stop brain tumours cells invading through a 3D matrix. This implies that in some, and perhaps many, tumours it is not the best known things that PTEN does that explain why it gets damaged, but instead it must be these new ways that PTEN can work that we know much less about."
The work also identified a 'gene signature' (showing which genes are turned on and off in particular cells) that is controlled by PTEN, which links to its control of invasion, but not its best recognised ways of working.
"Interestingly this gene signature also seemed to be recognisable in almost all of a large set of human brain tumour samples that lack or have damaged PTEN, providing more evidence that this new way in which PTEN works may be important in brain tumour development," said Dr Leslie.
"The key goals of future work in this area need to include understanding much more about these new ways in which PTEN can work and whether they show us new ways to develop drugs to treat brain and other tumours."
The work of Dr Leslie and the Dundee team has been supported by funding from the Medical Research Council and the Association for International Cancer Research.
NOTES TO EDITORS
LIFE SCIENCES AT DUNDEE
With more than 1000 staff and research students and external funding in excess of £30 million per year, the College of Life Sciences at the University of Dundee is one of the largest and most productive research institutes in Europe. Our reputation is genuinely global and is reflected in the fact that researchers in our laboratories represent no fewer than 58 different nationalities.
The University's achievements in the life sciences were recognised with a double win at the 2011 Biotechnology and Biological Sciences Research Council Awards where Dundee was first for `Greatest delivery of impact'. The University is the central hub for a multi-million pound biotechnology sector in the east of Scotland, which now accounts for 16% of the local economy.
We collaborate with the world's major pharmaceutical and biotechnology companies in the fight against diseases such as cancer, diabetes and rheumatoid arthritis. Our Drug Discovery Unit is actively developing drugs for the treatment of neglected tropical diseases including malaria and African sleeping sickness and translating innovative drug targets in oncology, eczema, type-2 diabetes, anti-bacterials and anti-virals.
MEDICAL RESEARCH COUNCIL
For almost 100 years the Medical Research Council has improved the health of people in the UK and around the world by supporting the highest quality science. The MRC invests in world-class scientists. It has produced 29 Nobel Prize winners and sustains a flourishing environment for internationally recognised research. The MRC focuses on making an impact and provides the financial muscle and scientific expertise behind medical breakthroughs, including one of the first antibiotics penicillin, the structure of DNA and the lethal link between smoking and cancer. Today MRC funded scientists tackle research into the major health challenges of the 21st century.
ASSOCIATION FOR INTERNATIONAL CANCER RESEARCH (AICR)
From its base in St Andrews, in Fife, AICR currently finances 204 active projects - 87 in the UK and 117 overseas. That's 196 scientists in 112 different institutions across 22 countries. We fund 20 different cancer types plus fundamental and all site projects, at an average cost of £167,542.
In alphabetical order, the 22 countries currently holding AICR grants are: Australia (13), Belgium( 1), Canada (2), Denmark (3), England (64), Finland (4), France( 9), Germany (4), Greece (4), Israel (4), Italy (29), Netherlands (14), New Zealand (1), Northern Ireland (1), Portugal (1), Scotland (20), Singapore (1), Spain (11), Sweden (3), Switzerland (6), USA (7), Wales (2).
The cost of this research is £38,464,304 which does not include the fellowships or take into account those projects that are only for one or two years.
Since its small beginnings 32 years ago, AICR's overall spend on research to date has been £150,628,908, on 1837 projects throughout 32 different countries.
For media enquiries contact:
Head, Press Office
University of Dundee
Nethergate, Dundee, DD1 4HN
TEL: 01382 384910
E-MAIL: [email protected]
MOBILE: 07800 581902